Nanobiotix Aktie
3,39EUR | -0,05EUR | -1,57% |
WKN DE: A1J7EB / ISIN: FR0011341205
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 97,30 |
Baillie Gifford & Co. | 5,18 |
Baillie Gifford Overseas Growth Fund - Global Discovery Fund | 2,88 |
Laurent Lévy, PhD | 2,40 |
Sycomore Fund SICAV - Europe Happy @ Work | 0,62 |
Government Pension Fund - Global (The) | 0,53 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 110 | 90 | 100 | 102 | 102 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,29 |
Bilanz (in Mio. EUR) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 46 | 125 | 93 | 52 | 87 |
Summe Anlagevermögen | 10 | 9 | 9 | 7 | 7 |
Summe Aktiva | 56 | 134 | 102 | 60 | 94 |
Bilanz (in Mio. EUR) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 45 | 49 | 46 | 53 | 51 |
Summe Fremdkapital | 58 | 64 | 75 | 87 | 96 |
Summe Eigenkapital | -2 | 70 | 27 | -27 | -2 |
Summe Passiva | 56 | 134 | 102 | 60 | 94 |
Adresse
60, rue de Wattignies, 75012 Paris | |
Telefon | +33 (1) 40-26-04-70 |
Fax | +33 (1) 40-26-04-44 |
Internet | http://www.nanobiotix.com |
Management
Alain Herrera
Member-Supervisory Board |
Anne-Juliette Hermant
Chief People Officer |
Anne-Marie Graffin
Deputy Chairman-Supervisory Board |
Bart van Rhijn
Chief Financial Officer |
Craig West
Senior Vice President-Investor Relations |
Enno Spillner
Member-Supervisory Board |
Gary M. Phillips
Chairman-Supervisory Board |
Laurent Lévy
Chairman-Executive Board & Chief Executive Officer |
Louis Kayitalire
Chief Medical Officer |
Margaret Galluzzi
Vice President & Head-Global Clinical Operations |
Patrick Tricoli
Global Head-Business Development |